

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 68211

Title: Correlation of hepatitis B surface antigen expression with clinicopathological and biochemical parameters in liver biopsies: A comprehensive study

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03656599

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Turkey

Manuscript submission date: 2021-05-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-17 10:45

Reviewer performed review: 2021-05-18 08:44

Review time: 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

**Peer-reviewer
statements**Peer-Review: [☒] Anonymous [☐] OnymousConflicts-of-Interest: [☐] Yes [☒] No**SPECIFIC COMMENTS TO AUTHORS**

This study elucidated the relationship between p-HBsAg levels in liver and HBsAg levels, HBV DNA levels in serum, and the treatment response in patients receiving entecavir treatment. This study had certain clinical significance. It demonstrated that the quantitative evaluation of HBsAg expression in pretreatment-naïve liver biopsies of patients with CHB may provide a prediction of the response to antiviral therapy, especially in cases with HBeAg positivity. In addition, there is a question: At the time of liver biopsy, most patients had elevated ALT, which was in line with the guidelines for antiviral therapy. Why did all patients in this study start ETV antiviral therapy 3 months after liver biopsy?